A Phase 2 interventional study of CM310 and Placebo in Asthma, sponsored by Keymed Biosciences Co.Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-02-28.
Sponsored by Keymed Biosciences Co.Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.
Among the 251 studies in Asthma with a site in China, this one is the 141st largest by enrollment of the 182 interventional ones that give a count, is one of 21 that started in 2022, is one of 39 in phase 2, and was the 114th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in China, United States, Argentina and 2 more countries
Ages 18–85
AstraZeneca · Sites in China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Sites in China
Ages 18–70
Shanghai Pulmonary Hospital, Shanghai, China · Sites in China
Ages 18+
Chiesi Farmaceutici S.p.A. · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
251 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 46 · Phase 3 50 · Phase 4 18
First in 1998; this study’s year is marked. 21 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 203 across the 182 interventional studies, 407 across the 69 observational. Of the 116 that completed or were terminated, 30 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
140 of 251 have an industry lead sponsor. The 10 most frequent:
Keymed Biosciences Co.Ltd is the lead sponsor of 68 studies on the registry; 34 are open to participants now.
Keymed Biosciences Co.Ltd has 4 studies filed under Asthma — fewer than ten, so there is no comparison to draw.
28 of the studies in Asthma with a site in China that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06323213Phase 3Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Efficacy and Safety Study of 610 in Patients With Severe Asthma | 2027-02 |
| NCT06895460Phase 3The First Affiliated Hospital with Nanjing Medical UniversityA Trial on the Treatment of Bronchial Asthma With Budesonide Formoterol Combined With Immune Modulators (Staphylococcus and Neisseria Tablets) | 2027-06-30 |
| NCT06653322Phase 3Guangdong Hengrui Pharmaceutical Co., LtdA Multi-centered,Randomized,Double-blind,Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma | 2027-09 |
| NCT06471257Phase 3AstraZenecaA Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma | 2027-10-04 |
| NCT06307665Phase 3AstraZenecaEvaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma | 2027-10-13 |
Add all 28 to your calendar (.ics) → With an account.
Among the 251 studies in Asthma with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe asthma.
The study consists of three periods, including an up to 4-week screening period, a 24-week randomized treatment period, and a 8-week safety follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CM310 is injected subcutaneously (SC) with a loading dose of 600 mg at the first dose, and then 300 mg each time, once every 2 weeks (Q2W) for a total of 12 doses.
Drug: CM310
CM310 is injected subcutaneously (SC) with a loading dose of 300 mg at the first dose, and then 150 mg each time, once every 2 weeks (Q2W) for a total of 12 doses.
Drug: CM310
Subcutaneous injection (SC), once every 2 weeks (Q2W) for a total of 12 doses.
Other: Placebo
CM310 Recombinant Humanized Monoclonal Antibody Injection
Placebo
Change from baseline in pre-bronchodilator FEV1 (forced expiratory volume in 1 second) at 12 weeks.
Absolute change from baseline in pre-bronchodilator FEV1 in each dose group at 12 weeks of CM310 treatment compared with placebo.
Time frame: 12 weeks
Change from baseline in pre-bronchodilator FEV1 at each evaluation time point.
Absolute change from baseline in pre-bronchodilator FEV1 at each evaluation time point.
Time frame: 24 weeks
Percent change from baseline in pre-bronchodilator FEV1 at each evaluation time point.
Percent change from baseline in pre-bronchodilator FEV1 at each evaluation time point.
Time frame: 24 weeks
Annualized rate of subjects experiencing severe asthma exacerbations.
Annualized rate of subjects experiencing severe asthma exacerbations during the 24-week randomized treatment period.
Time frame: 24 weeks
Time to the first onset of the severe asthma exacerbation event.
Time from baseline to the first onset of the severe asthma exacerbation event.
Time frame: 24 weeks
Annualized rate of subjects experiencing the event of loss of asthma control (LOAC).
Annualized rate of subjects experiencing the event of loss of asthma control (LOAC) during the 24-week randomized treatment period.
Time frame: 24 weeks
Time to the onset of the first event of LOAC.
Time from baseline to the onset of the first event of LOAC.
Time frame: 24 weeks
FEV1 percentage of predicted value (FEV1% Pred)
FEV1 percentage of predicted value (FEV1% Pred)
Time frame: 32 weeks
Peak diurnal and nocturnal expiratory flow (PEF)
Peak diurnal and nocturnal expiratory flow (PEF)
Time frame: 32 weeks
Forced vital capacity (FVC)
Forced vital capacity (FVC)
Time frame: 32 weeks
Maximal mid-expiratory flow (MMEF)
Maximal mid-expiratory flow (MMEF)
Time frame: 32 weeks
Change from baseline of FEV1 after the use of bronchodilator.
Change from baseline of FEV1 after the use of bronchodilator.
Time frame: 32 weeks
Change from baseline in the Asthma Control Questionnaire-5 (ACQ-5) score at each evaluation time point.
The ACQ-5 is a questionnaire used to evaluate the degree of asthma control. Each question is scored from 0 to 6 (on a 7-point scale) according to its severity. The higher the score, the less satisfactory symptom control is.
Time frame: 32 weeks
Change from baseline in asthma symptom score at each evaluation time point.
Patients will record total symptom scores in morning(a 0-4 scale, with 0=no symptoms, 4=inability to fall asleep at night due to symptoms) and afternoon (a 0-5 scale, with 0=no symptoms, 5=severe symptoms, unable to work or perform daily activities).
Time frame: 32 weeks
Incidence of Adverse events (AEs)
Incidence of AEs, including any abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing.
Time frame: 32 weeks
Trough concentration at steady-state of CM310
To evaluate the trough concentration at steady-state of CM310 for each dose group. Population pharmacokinetic analysis is performed using a nonlinear mixed-effects model.
Time frame: 32 weeks
Human thymus and activation-regulated chemokine (TARC)
Change from baseline in TARC at each evaluation time point for each dose group.
Time frame: 32 weeks
Fractional exhaled nitric oxide (FeNO).
Change from baseline in FeNO at each evaluation time point for each dose group.
Time frame: 32 weeks
Total IgE (immunoglobulin E)
Change from baseline in total IgE at each evaluation time point for each dose group.
Time frame: 32 weeks
Anti-drug antibodies (ADAs) and neutralizing antibodies (Nabs).
Incidence of anti-drug antibodies (ADAs) and neutralizing antibodies (Nabs) (if applicable).
Time frame: 32 weeks
Ran from Jan 2022 to primary completion in Sep 2023, 20 months.
Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 20 months is above that.
Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Stapokibart